Higher Insulin Sensitivity and Impaired Insulin Secretion in Cachetic Solid Ehrlich Tumour-Bearing Mice

Abstract

Insulin secretion is mainly regulated by blood glucose concentration. On the other hand, changes in peripheral insulin sensitivity induce compensatory adaptations in pancreatic β-cells to maintain normoglycaemia. Tumour presence causes dramatic alterations in glucose homeostasis and insulin secretion because of the high glucose consumption by the tumour cells. Here, we investigated insulin secretion in solid Ehrlich tumour-bearing mice in association with cachexia. For that, male adult Swiss mice were subcutaneously inoculated with solid Ehrlich tumour cells and sacrificed at 14 days after tumour implantation (SET), while control mice received saline alone (CTL). Insulin secretion, following different stimuli, glucose tolerance, and insulin sensitivity as well as the expression of key proteins involved in insulin secretion was assessed. The SET group showed decreased glycaemia, insulinaemia, hepatic glycogen and body weight, and increased plasma free fatty acids and triglycerides, characteristics of cancer cachexia. A very interesting finding in this study was the development of higher glucose tolerance and insulin sensitivity in SET group. The dose-response curve of insulin secretion to increasing glucose concentrations (2.8–22.2 mM) showed an EC₅₀ of 10 mM glucose for CTL mice and 13 mM glucose for SET mice. Insulin secretion was significantly reduced in SET islets at 30 mM KCl, 100 μM carbachol, 20 mM arginine, and 20 mM leucine. Moreover, AKT, PKA, PKC, and AchRM3 expressions were reduced by 17% to 24% in SET animals. These results, mainly the augmented insulin sensitivity, show that SET is an interesting model to study alterations in pancreatic function and carbohydrate metabolism in cancer cachexia.

Key words

cachexia - pancreatic β-cells - protein expression

• References

• 1 Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000; 49: 1751-1760
• 2 Henquin JC. The dual control of insulin secretion by glucose involves triggering and amplifying pathways in β-cells. Diabetes Res Clin Pract 2011; 93: 27-31
• 3 Ma J, Giovannuci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, Stampfer MJ. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004; 96: 546-553
• 4 Healy LA, Ryan AM, Carroll P, Ennis D, Crowley V, Boyle T, Kennedy MJ, Connolly E, Reynolds JV. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol 2010; 22: 281-288
• 5 Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: A significant risk factor of endometrial cancer. Gynecol Oncol 2012; 125: 751-757
• 6 Cui Y, Andersen DK. Diabetes and pancreatic cancer. Endocr Relat Cancer 2012; 19: F9-F26
• 7 Fernandes LC, Machado UF, Nogueira CR, Carpinelli AR, Curi R. Insulin secretion in Walker 256 tumour cachexia. Am J Physiology 1990; 258: 1033-1036
• 8 Hursting SD, Berguer NA. Energy balance, host related factors and cancer progression. J Clin Oncol 2010; 28: 4058-4065
• 9 Tisdale MJ. Cancer Cachexia. Curr Opin Gastroenterol 2010; 26: 146-151
• 10 Asp ML, Tian M, Wendel AA, Belury MA. Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int J Cancer 2009; 126: 756-763
• 11 Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells. J Biol Chem 1995; 270: 16918-16925
• 12 Tigerina AJ. The biochemical basis of metabolism in cancer cachexia. Dimens Crit Care Nurs 2004; 23: 237-243
• 13 Rohdenburg GL, Bernhard A, Krehbiel O. Sugar tolerance in cancer. JAMA 1919; 72: 1528-1530
• 14 Tayek JA. A review of cancer cachexia and abnormal glucose in humans with cancer. J Am Coll Nutr 1992; 11: 445-456
• 15 Argilés JM, Alvarez B, López-soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev 1997; 17: 477-498
• 16 Sugiura K. Tumor transplantation. In: GAY WI. Methods of Animal Experimentation. Academic Press; New York and London: 1965. 2. 171-222
• 17 Stewart LH. The cancer investigator. Cancer Res 1959; 19: 804-818
• 18 Silva RJ, Silva MG, Vilela LC, Fecchio D. Cytokine profile of Ehrlich ascites tumor treated with Bothrops jararaca venom. Mediators Inflamm 2002; 11: 197-201
• 19 Rafacho A, Giozzet AGV, Boschero AC, Bosqueiro JR. Functional alterations in endocrine pancreas of rats with different degrees of dexamethasone-induced insulin resistance. Pancreas 2008; 36: 284-293
• 20 El Razi Neto S, Zorn TMT, Curi R, Carpinelli AR. Impairment of insulin secretion in pancreatic islets isolated from Walker 256 tumor-bearing rats. Am J Physiol Cell Physiol 1996; 271: C804-C809
• 21 Rebeca R, Bracht L, Noleto GR, Martinez GR, Cadena SMSC, Carnieri EGS, Rocha MEM, de Oliveira MBM. Production of cachexia mediators by Walker 256 cells from ascitic tumors. Cell Biochem Funct 2008; 26: 731-736
• 22 Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Fanelli FR, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin Nutr 2008; 27: 793-799
• 23 Argilés JM, López-Soriano FJ, Busquets S. Novel approaches to the treatment of cachexia. Drug Discov Today 2008; 13: 73-78
• 24 Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009; 89: 381-410
• 25 Argilés JM, López-Soriano FJ, Busquets S. Mechanisms and treatment of cancer cachexia. Nutr Metab Cardiovasc Dis 2013; 23 (Suppl. 01) S19-S24
• 26 Arner P. Lipases in cachexia. Science 2011; 333: 163-164
• 27 Das SK. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011; 333: 233-238
• 28 Pinto JA, Folador A, Bonato SJ, Aikawa J, Yamazaki RK, Pizato N, Facin M, Grohs H, de Oliveira HHP, Naliwaiko K, Ferraz AC, Nishiyama A, Fernandez R, Curi R, Fernandes LC. Fish oil supplementation in F1 generation associated with naproxen, clenbuterol, and insulin administration reduce tumor growth and cachexia in Walker 256 tumor-bearing Rats. J Nutr Biochem 2004; 15: 358-365
• 29 Nune EA, Kuczera D, Brito GAP, Bonatto SJR, Yamazaki RK, Tanhoffer RA, Mund RC, Kryczyk M, Fernandes LC. β-Hydroxy-β-methylbutyrate supplementation reduces tumor growth and tumor cell proliferation ex vivo and prevents cachexia in Walker 256 tumor-bearing rats by modifying nuclear factor-κB expression. Nutr Res 2008; 28: 487-493
• 30 Hirai K, Ishiko O, Tisdale MJ. Mechanism of depletion of liver glycogen in cancer cachexia. Biochem Biophys Res Commun 1997; 241: 49-52
• 31 Korekane H, Nishikawa A, Iamamura K. Mechanisms mediating metabolic abnormalities in the livers of Ehrlich ascites tumor-bearing mice. Arch Biochem Biophys 2003; 412: 216-222
• 32 Lohsiriwat V, Lohsiriwat D, Boonnuch W, Chinswangwatanakul V, Akaraviputh T, Lert-akayamanee N. Pre-operative hypoalbuminemia is a major risk factor for postoperative complications following rectal cancer surgery. World J Gastroenterol 2008; 28: 1248-1251
• 33 Kemik O, Sumer A, Kemik AS, Hasirci I, Purisa S, Dulger AC, Demiriz B, Tuzun S. The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol 2010; 8: 85
• 34 Farrell G. Insulin resistance, obesity, and liver cancer. Clin Gastroentrol Hepatol 2014; 12: 117-119
• 35 Westley RL, May FEB. A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors. Int J Endocrinol 2013; 2013: 632461
• 36 Beck SA, Tisdale MJ. Effect of insulin on weight loss and tumour growth in a cachexia model. Br J Cancer 1989; 59: 677-681
• 37 Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, Vanelli GB, Brand R, Goldfine ID, Vigneri R. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990; 86: 1503-1510
• 38 Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA, Molinolo AA, Kurshan N, Mejia W, Stefania S, Yakar S, Wood TL, LeRoith D. Insulin mediated acceleration of breast cancer development and progression in a non obese model of type 2 diabetes. Cancer Res 2010; 70: 741-751
• 39 Rydén M, Agustsson T, Laurencikiene J, Britton T, Sjolin E, Isaksson B, Permet J, Arner P. Lipolysis – not inflammation, cell death, or lipogenesis – is involved in adipose tissue loss in cancer cachexia. Cancer 2008; 113: 1695-1704
• 40 Bing C, Taylor S, Tisdale MJ, Williams G. Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J Neurochem 2001; 79: 1004-1012
• 41 Gromada J, Hughes TE. Ringing the dinner bell for insulin: Muscarinic M3 receptor activity in the control of pancreatic b cell function. Cell Metab 2006; 3: 390-392
• 42 de Azua IR, Gautam D, Guettier JM, Wess J. Novel insights into the function of β-cell M3 muscarinic acetylcholine receptors: therapeutic implications. Trends Endocrinol Metab 2011; 22: 74-80
• 43 Ishikawa T, Iwasaki E, Kanatani K, Sugino F, Kaneko O, Nakayama K. Involvement of novel protein kinase C isoforms in carbachol-stimulated insulin secretion from rat pancreatic islets. Life Sci 2005; 77: 462-469
• 44 Nesher R, Anteby E, Yedovizky M, Warwar N, Kaiser N, Cerasi E. Cell protein kinase and the dynamics of the insulin. Diabetes 2002; 51: s68-s73